|
Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. |
|
|
No Relationships to Disclose |
|
|
Employment - Blue Cross and Blue Shield of Massachusetts; Tempus |
|
|
|
Stock and Other Ownership Interests - Tempus |
|
|
|
|
|
|
Stock and Other Ownership Interests - Tempus |
Travel, Accommodations, Expenses - Tempus |
|
|
|
Stock and Other Ownership Interests - Tempus |
|
|
|
Stock and Other Ownership Interests - Tempus |
|
|
|
|
|
|
Stock and Other Ownership Interests - Tempus |
|
|
|
Stock and Other Ownership Interests - Tempus |
|
|
|
Stock and Other Ownership Interests - Tempus |
|
|
|
Stock and Other Ownership Interests - Tempus; Zocdoc |
|
|
|
Stock and Other Ownership Interests - Tempus |
Patents, Royalties, Other Intellectual Property - Tempus (Inst) |
Travel, Accommodations, Expenses - Tempus |
|
|
Employment - Northwest Medical Specialties; University of Washington (I) |
Leadership - Northwest Medical Specialties; Quality Cancer Care Alliance |
Stock and Other Ownership Interests - Northwest Medical Specialties |
Honoraria - American Journal of Managed Care; Cardinal Health; Novartis; Puma Biotechnology |
Research Funding - Northwest Medical Specialties |
Expert Testimony - Northwest Medical Specialties |
Travel, Accommodations, Expenses - Northwest Medical Specialties |
Other Relationship - All4Cure (I); Northwest Medical Specialties; Quality Cancer Care Alliance |
|
|
Stock and Other Ownership Interests - Acceleron Pharma; Agios; Bluebird Bio; Genprex; Illumina; IQvia; Karyopharm Therapeutics; Karyopharm Therapeutics (I); Molecular Templates; Pacific Biosciences; Quintiles; ZIOPHARM Oncology |
Consulting or Advisory Role - Tempus |
|
|
No Relationships to Disclose |
|
|
Research Funding - Agendia; Amgen; Astellas Pharma; Biodeix; Bristol-Myers Squibb; Calithera Biosciences; Celgene; Clinical Genomic; Genomic Health; Laboratory for Advanced Medicine; Natera; Novartis; Paradigm; PrognomIQ; Sanofi; Tempus |
|
|
Employment - Oncology Consultants |
Leadership - Oncology Consultants |
Stock and Other Ownership Interests - Oncology Consultants; Roche; Spectrum Pharmaceuticals; Tersera; zogen |
Honoraria - Agendia; Guardant Health; Tempus |
Consulting or Advisory Role - Tersera |
Speakers' Bureau - Agendia; Guardant Health; Tempus |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Genentech/Roche (Inst); Immatics (Inst); ImmunityBio (Inst); Immutep (Inst); IncMed (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); NovoCure (Inst); Sermonix Pharmaceuticals (Inst); Tersera (Inst); Thrive Earlier Detection Corp (Inst); Turning Point Therapeutics (Inst) |
Travel, Accommodations, Expenses - Agendia; Guardant Health; Tempus |
|
|
Employment - Lilly; Tempus |
Leadership - cereius; Monte Rosa Therapeutics; zentalis |
Stock and Other Ownership Interests - Lilly |
|
|
|
Research Funding - Tempus |
Travel, Accommodations, Expenses - Parexel; Tempus |